

Discover a New Treatment Option for Some Patients With Triple-Class Refractory Multiple Myeloma

Join *OncLive*® and Oncopeptides on

- **Tuesday, April 13 at 6pm ET or 8:30pm ET**
- **Wednesday, April 14 at 12pm ET or 3pm ET**

for a live broadcast featuring Dr. Mikhael and Dr. Richter, who will discuss a newly approved therapy for adult patients with multiple myeloma who have received at least four prior lines of therapy and are triple-class refractory.

JOIN THE EXPERTS:



Joseph Mikhael, MD

Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute (TGen)
City of Hope Cancer Center



Joshua Richter, MD

Assistant Professor of Medicine,
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Multiple Myeloma
Blavatnik Family – Chelsea Medical Center at Mount Sinai

In this Live Broadcast, Dr. Mikhael and Dr. Richter will:



Explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody



Review safety, dosing, and administration of the agent



Discuss efficacy data from a key clinical trial for this therapy



Address the challenges of treating some patients with triple-class refractory multiple myeloma

Register at studio.mjhassoc.com/reach/oncopeptides-mm-broadcast

OncLive®